Japanese Biotech Reports New, Safer Way To Create iPS Cells
This article was originally published in PharmAsia News
Executive SummaryJapan's Dnavec, a biotech start-up company, says it found a way to create induced pluripotent stem cells by using a virus whose cells are kept intact. Dnavec's researchers said their new method goes a long way to lower the risk of the cells becoming cancerous. The work, soon to be published in a science journal, is considered significant because with the team's method the genes carried by the virus disappear after the iPS cells are created, making it far less likely they would grow out of control and form a tumor after being transplanted. (Click here for more - a subscription may be required
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.